HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.

Abstract
UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.
AuthorsJohn R Pollard
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 1 Pg. 101-7 (Jan 2008) ISSN: 1472-4472 [Print] England
PMID18183537 (Publication Type: Journal Article, Review)
Chemical References
  • Anticonvulsants
  • Pyrrolidinones
  • Seletracetam
Topics
  • Animals
  • Anticonvulsants (chemical synthesis, pharmacology, therapeutic use)
  • Epilepsy (drug therapy)
  • Humans
  • Parkinson Disease (drug therapy)
  • Pyrrolidinones (chemical synthesis, pharmacology, therapeutic use)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: